21 July 2021

READ MOREAkston Biosciences Announces Commercial Supply Agreement of Seppic’s Adjuvant to Formulate Akston Shelf-stable COVID-19 Vaccine at Global Scale

8 July 2021

READ MOREAkston Biosciences Announces Positive Phase I Data for Second-Generation COVID-19 Vaccine Candidate

1 September 2020

READ MORETRACER to support Akston Biosciences’ Phase 1 clinical study of AKS-452

9 April 2020

READ MOREAkston Biosciences Completes Series E Preferred Stock Financing

17 May 2018

READ MOREAkston Biosciences Completes Series D Preferred Stock Financing

22 February 2018

READ MOREAkston Biosciences Awarded Phase II SBIR by NIH/NIDDK

16 March 2017

READ MOREHelmsley Charitable Trust and Akston Biosciences Corporation Announce Partnership to Advance Novel Technology to Treat Type 1 Diabetes

12 January 2015

READ MOREUltra-long-acting recombinant insulin for the treatment of diabetes mellitus in dogs